

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

APC/Cyanine7 anti-human CD3

RRID:AB_10645474

Type: Antibody

Proper Citation

BioLegend Cat# 344818, RRID:AB_10645474

Antibody Information

URL: http://antibodyregistry.org/AB_10645474

Proper Citation: BioLegend Cat# 344818, RRID:AB_10645474

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Cyanine7 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone SK7

Antibody ID: AB_10645474

Vendor: BioLegend

Catalog Number: 344818

Alternative Catalog Numbers: 344817

Record Creation Time: 20250819T221312+0000

Record Last Update: 20250820T012950+0000

Ratings and Alerts

No rating or validation information has been found for APC/Cyanine7 anti-human CD3.

No alerts have been found for APC/Cyanine7 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ma T, et al. (2026) Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV rebound. *Immunity*, 59(5), 1454.

Li F, et al. (2026) Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias. *Cell*, 189(7), 1942.

Carp DM, et al. (2026) Single-cell assessment of iron content in primary human T cells using laser ablation inductively coupled plasma mass spectrometry. *Cell reports methods*, 6(4), 101343.

Reiné J, et al. (2026) Host-microbial interactions at the nasal mucosa in young children and adults: A retrospective, cross-sectional study. *Cell reports*, 45(5), 117346.

Mishra R, et al. (2026) Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial. *Cancer immunology research*, 14(4), 543.

Huang B, et al. (2026) Single-cell transcriptional and epigenomic landscape of human blood immune cells across the lifespan. *Cell reports*, 45(3), 117072.

Pham-Danis C, et al. (2025) Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. *Cancer cell*, 43(3), 482.

Cook MS, et al. (2025) CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. *Cell reports*, 44(7), 115973.

Dong MH, et al. (2025) Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy. *Med (New York, N.Y.)*, 6(9), 100704.

Sureshchandra S, et al. (2025) Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils. *Immunity*, 58(12), 3130.

Zhang J, et al. (2024) Pyroptotic T cell-derived active IL-16 has a driving function in ovarian endometriosis development. *Cell reports. Medicine*, 5(3), 101476.

Kirschenbaum D, et al. (2024) Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. *Cell*, 187(1), 149.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. *Cell reports. Medicine*, 5(3), 101469.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. *Cell reports. Medicine*, 5(11), 101827.

Weskamm LM, et al. (2024) Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach. *iScience*, 27(8), 110470.

Wang Y, et al. (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. *Cell reports. Medicine*, 5(6), 101580.

Herrera-De La Mata S, et al. (2023) Cytotoxic CD4⁺ tissue-resident memory T cells are associated with asthma severity. *Med (New York, N.Y.)*, 4(12), 875.

George MS, et al. (2023) Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function. *iScience*, 26(8), 107280.

Muliaditan T, et al. (2021) Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. *Cell reports. Medicine*, 2(12), 100457.